Randomized Phase 2 study in front-line setting progressing well, with nine sites actively recruiting and patient treatment ongoingData update expected in 2027, with trial completion in ...
Compass Therapeutics is rated Buy, with risk/reward favoring upside after a sharp post-data selloff. Click here to read more ...
Kelun-Biotech, listed under stock code 6990.HK, announced its Phase III OptiTROP-Lung06 trial of sac-TMT combined with ...
As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated the superiority of replacing ...
As President Trump resumes his war, the focus is now on the Strait of Hormuz. But it remains unclear how far the U.S.
Delhi Metro has begun construction of the 12.37-km Inderlok-Indraprastha underground corridor, a Phase-IV project that will ...
India's economic fundamentals are stronger than they have been through much of the past two decades, but the country's next ...
The grid faltered during last weekend’s heat wave. Now BGE is asking regulators to approve a massive new transmission system ...
After monetising Big Sandy, Paul Lloyd is plan to turn Prairie Lithium’s Saskatchewan brine project from DLE promise into ...
Phase Two of the Shah Alam Light Rail Transit Line 3 (LRT3) project remains part of the government’s long term development plan and will include ...
Detailed price information for Medicenna Therapeutics Corp (MDNA-T) from The Globe and Mail including charting and trades.
One year ago, Congress defunded public media. Now that we're 100% community funded, please become a sustaining member or increase your existing membership today. The first phase of the Los Angeles ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results